191 related articles for article (PubMed ID: 36867679)
1. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
[TBL] [Abstract][Full Text] [Related]
2. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
[TBL] [Abstract][Full Text] [Related]
3. Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.
Jin H; D'Urso V; Neuteboom B; McKenna SD; Schweickhardt R; Gross AW; Fomekong Nanfack Y; Paoletti A; Carter C; Toleikis L; Fluck M; Scheuenpflug J; Cai T
Oncoimmunology; 2021; 10(1):1958590. PubMed ID: 34484871
[TBL] [Abstract][Full Text] [Related]
4. FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Sow HS; Benonisson H; Breukel C; Visser R; Verhagen OJHM; Bentlage AEH; Brouwers C; Claassens JWC; Linssen MM; Camps M; van Hall T; Ossendorp F; Fransen MF; Vidarsson G; Verbeek JS
Int J Cancer; 2019 Jan; 144(2):345-354. PubMed ID: 30259976
[TBL] [Abstract][Full Text] [Related]
5. Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity.
Smith AJ; Thurman RE; Zeng W; Grogan B; Lucas S; Gutierrez G; Heiser RA; Wo SW; Blackmarr A; Peterson S; Gardai SJ
Front Immunol; 2023; 14():1280986. PubMed ID: 38022590
[TBL] [Abstract][Full Text] [Related]
6. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
7. Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.
Izadi S; Gumpelmair S; Coelho P; Duarte HO; Gomes J; Leitner J; Kunnummel V; Mach L; Reis CA; Steinberger P; Castilho A
Plant Biotechnol J; 2024 May; 22(5):1224-1237. PubMed ID: 38050338
[TBL] [Abstract][Full Text] [Related]
8. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.
Dahan R; Barnhart BC; Li F; Yamniuk AP; Korman AJ; Ravetch JV
Cancer Cell; 2016 Jun; 29(6):820-831. PubMed ID: 27265505
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
[TBL] [Abstract][Full Text] [Related]
11. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
12. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.
Bournazos S; Chow SK; Abboud N; Casadevall A; Ravetch JV
J Clin Invest; 2014 Feb; 124(2):725-9. PubMed ID: 24401277
[TBL] [Abstract][Full Text] [Related]
13. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
[TBL] [Abstract][Full Text] [Related]
15. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
16. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
Hamilton G; Rath B
Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
[TBL] [Abstract][Full Text] [Related]
17. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
18. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
[TBL] [Abstract][Full Text] [Related]
19. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates.
Tada M; Aoyama M; Ishii-Watabe A
J Pharm Sci; 2020 Jan; 109(1):576-583. PubMed ID: 31676270
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
